Syncona
Limited
Change in
Investment Manager
12 December 2017
Syncona Ltd, a leading healthcare company focused on investing
in and building global leaders in life science, today announces
that it has appointed its subsidiary Syncona Investment Management
Limited (SIML) as its investment manager and AIFM for the purposes
of the AIFM Directive. This appointment is with effect from
12 December 2017 and is as envisaged
at the time of the change of the Company’s investment policy and
acquisition of the life science portfolio of Syncona Partners LLP
approved by the Company’s shareholders in December 2016.
BACIT (UK) Limited, the former investment manager and AIFM of
the Company, continues to be engaged by SIML as a sub-delegate to
manage the funds portfolio, on the same terms.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031
Notes to Editors
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on
investing in and building global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders. Our current investment portfolio consists
of seven high quality companies in life science and a leading range
of fund investments.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses. We are
established leaders in gene therapy, cell therapy and advanced
diagnostics, and focus on delivering dramatic efficacy for patients
in areas of high unmet need.
Our market leading funds portfolio seeks to generate superior
returns by investing in long only and alternative investment funds.
This represents a productively deployed evergreen funding base
which enables us to take a long term approach to investing in life
sciences as we target the best new opportunities and support our
existing portfolio companies to grow and succeed.
Syncona is aligned with two of the premium charitable funders in
UK science, the Wellcome Trust, original founder of Syncona, and
Cancer Research UK, both of which are significant shareholders in
our business. We make a donation of 0.3% of Net Asset Value
to a range of charities each year.